Arthritis News and Research

Latest Arthritis News and Research

Ipsen, Active Biotech to present data from tasquinimod phase II trial on CRPC at ASCO 2012

Active Biotech and Ipsen will present tasquinimod (TASQ), their prostate cancer drug candidate, at the scientific conference "2012 ASCO Annual Meeting" to be held in Chicago (USA) on 1-5 June 2012.

18 May 2012

Pharmos completes levotofisopam phase 2a trial on hyperuricemia, gout

Pharmos Corporation announced that it has successfully completed a proof-of-concept clinical trial using its compound levotofisopam (S-tofisopam) to treat patients with hyperuricemia and gout.

18 May 2012

Medgenics’ EPODURE receives FDA clearance to proceed into clinical trials

Medgenics, Inc., developer of the novel Biopump technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced receipt of clearance from the U.S. Food and Drug Administration to proceed with a Phase IIb clinical trial of EPODURE for the treatment of anemia in patients undergoing renal dialysis.

18 May 2012

Updated results from Amgen’s blinatumomab Phase 2 study on ALL

Amgen today announced updated results from a Phase 2 study that showed treatment with blinatumomab (AMG 103) helped achieve a high-rate of complete response (CR) in 72 percent of adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL) treated in the study.

17 May 2012

National Psoriasis Foundation awards more than $2 million for research

Twenty-six scientists have received a total of $2.06 million in grants from the National Psoriasis Foundation to study psoriasis—the most common autoimmune disease in the country, affecting as many as 7.5 million Americans—and psoriatic arthritis, an inflammatory joint and tendon disease.

16 May 2012

Researchers map processes that power health benefits of omega-3 fatty acids

For the first time, researchers at the University of California, San Diego have peered inside a living mouse cell and mapped the processes that power the celebrated health benefits of omega-3 fatty acids. More profoundly, they say their findings suggest it may be possible to manipulate these processes to short-circuit inflammation before it begins, or at least help to resolve inflammation before it becomes detrimental.

16 May 2012

Biomarker test can accurately detect early arthritis symptoms

More than 27 million adults currently suffer from osteoarthritis, which is the most common form of arthritis. In the past, doctors have been unable to diagnose patients with arthritis until they begin to show symptoms, which include joint pain and stiffness. By the time these symptoms are present, it is often too late for preventive and minimally invasive treatment options to be effective. Now, a research team from the University of Missouri's Comparative Orthopaedic Laboratory has found a way to detect and predict arthritis before patients begin suffering from symptoms.

16 May 2012

Study identifies how skeletal muscle stem cells respond to muscle injury

A study conducted by Children's Hospital & Research Center Oakland scientists identifies how skeletal muscle stem cells respond to muscle injury and may be stimulated to improve muscle repair in Duchenne Muscular Dystrophy, a severe inherited disease of muscle that causes weakness, disability and, ultimately, heart and respiratory failure.

15 May 2012

Study describes new compounds that inhibit PRMT1 enzyme

Scientists at The Scripps Research Institute have found the first chemical compounds that act to block an enzyme that has been linked to inflammatory conditions such as asthma and arthritis, as well as some inflammation-promoted cancers.

11 May 2012

Osiris Therapeutics first quarter total revenues decrease to $4.6M

Osiris Therapeutics, Inc., the leading stem cell company focused on developing and commercializing products to treat medical conditions in inflammatory, cardiovascular, orthopedic, and wound healing markets, announced today its results for the first quarter ended March 31, 2012.

11 May 2012

African-Americans with scleroderma have more antibodies linked to severe complications

A new analysis finds that compared to Caucasians, African-Americans with systemic scleroderma have more antibodies in the blood that are linked to severe complications and an increased likelihood of death. They say this finding, published today in Arthritis & Rheumatism, suggests physicians can use these disease markers to screen and treat scleroderma patients proactively.

11 May 2012

Rituximab does not appear to benefit children with INS

The drug rituximab, an antibody that targets the immune system and is often used to treat immune disorders such as lymphoma and arthritis, has recently emerged as a potential treatment for a childhood kidney disorder known as idiopathic nephrotic syndrome.

11 May 2012

Preclinical evidence demonstrates link between psoriasis and cardiovascular disease

The link between psoriasis and cardiovascular events has been observed for years, however the mechanics were unknown. For the first time, Case Western Reserve University School of Medicine researchers have discovered preclinical evidence demonstrating that the inflammatory skin disease leads to cardiovascular disease. Further, the research demonstrated that aggressive reversal of psoriasis reduces the cardiovascular risk as well.

11 May 2012

African Americans have more severe complications from scleroderma

African Americans have more severe complications from systemic sclerosis, also known as scleroderma, than Caucasians. Findings published today in, Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR), show that compared with Caucasians, African-American patients were more likely to have antibodies that increased frequency and severity of pulmonary fibrosis, which is associated with decreased survival.

10 May 2012

Arthritis rates set to soar

According to new estimates the number of people with arthritis is set to soar with predictions that 1,500,000 Scots will be living with the condition by 2030.

10 May 2012

Arthritis management tips from NYU Langone

New biologics and drug therapies, clinical techniques and advanced imaging technology help clinicians and researchers evaluate and identify arthritis sooner. This earlier intervention can help return arthritis patients to an active lifestyle faster, with better long-term outcomes.

10 May 2012

FDA AAC recommends approval of Pfizer’s tofacitinib for RA

Pfizer Inc. announced today that the Arthritis Advisory Committee to the U.S. Food and Drug Administration (FDA) voted 8-2 to recommend approval of the investigational agent tofacitinib for the treatment of adult patients with moderately to severely active rheumatoid arthritis.

10 May 2012

Report notes rise in obesity slowing, but still huge health, cost problem

The obesity rate may rise to 42 percent from about a third of the U.S. population by 2030 if nothing changes, according to a report. Preventing that increase may save about $550 billion in medical costs over the next 20 years, Eric Finkelstein, the study author and an associate research professor at Duke University, said during a press briefing.

9 May 2012

Highlights of orthopaedic research studies in JBJS

Below are highlights of orthopaedic research studies appearing in the May 2, 2012 issue of the Journal of Bone and Joint Surgery (JBJS), as well as the issue's full Table of Contents.

9 May 2012

AARDA's Autoimmune Walk campaign surpasses first $20,000 fundraising milestone

Just a month after announcing its first-ever national "Autoimmune Walk: Linking Together for a Cure" campaign, American Autoimmune Related Diseases Association (AARDA) announced today that it has surpassed its first $20,000 fundraising milestone.

9 May 2012